Dexamethasone combined with berberine is an effective therapy for bleomycin-induced pulmonary fibrosis in rats

被引：23
作者：
Li, Li [1 ,2 ]
Li, Qiuhong [3 ]
Wei, Lei [1 ,2 ]
Wang, Zhongfu [1 ,2 ]
Ma, Wei [1 ,2 ]
Liu, Fangying [1 ,2 ]
Shen, Yanhua [1 ,2 ]
Zhang, Shanfang [1 ,2 ]
Zhang, Xiulian [1 ,2 ]
Li, Huiping [3 ]
Qian, Yechang [1 ,2 ]
机构：
[1] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Baoshan Branch, Dept Resp Dis, Shanghai 200431, Peoples R China
[2] Baoshan Dist Hosp Integrated Tradit Chinese & Wes, Dept Resp Dis, 181 You Yi Rd, Shanghai 201900, Peoples R China
[3] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Resp Med, 507 Zheng Min Rd, Shanghai 200433, Peoples R China
来源：
EXPERIMENTAL AND THERAPEUTIC MEDICINE | 2019年 / 18卷 / 04期
关键词：
pulmonary fibrosis; bleomycin; berberine plus dexamethasone; CXC chemokine ligand 14; matrix metalloproteinase 2; matrix metalloproteinase 9; Smad2; 3; MMP-9; INFLAMMATION; MODULATION; APOPTOSIS; CELLS;
D O I：
10.3892/etm.2019.7861
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Pulmonary fibrosis (PF) is a heterogeneous pathological process in lung tissues with a considerable mortality rate. Currently, combination therapy represents an effective approach to treat PF. Dexamethasone (Dxs) and berberine (BBR) are widely applied to inhibit the progression of PF. Dxs plus penehyclidine hydrochloride or alfacalcidol have been reported more effective in therapy compared with any single drug treatment. However, whether Dxs plus BBR induces an increased antifibrotic effect remains unknown. The current study aimed to evaluate the therapeutic effect of BBR plus Dxs in bleomycin (BLM)-induced PF. A PF model in rats was established and rats were divided into control, BLM, BBR, Dxs and BBR plus Dxs groups (n=9/group). On days 3, 7 and 14, blood samples were collected from the eyes of the rats (n=6/group). CXC chemokine ligand 14 (CXCL14), collagen I, collagen III, matrix metalloproteinase (MMP)2 and MMP9 serum levels were measured by ELISA. On day 14, all rats were sacrificed. Hematoxylin and eosin analysis, Masson staining and hydroxyproline (Hyp) assessment were performed to observe histopathological changes and collagen deposition. mRNA and protein levels of CXCL14, CXC chemokine receptor 4 (CXCR4), collagen I/III, alpha-smooth muscle actin (alpha-SMA), MMP2/9 and phosphorylated-Smad 2/3 in lung tissue were further evaluated. Similar effects in preventing lung damage were observed histopathologically for Dxs and BBR compared with the BLM group. These treatments further reduced levels of Hyp, CXCL14, CXCR4, collagen I/III, MMP2/9, alpha-SMA and p-Smad 2/3. The combination of Dxs and BBR exhibited increased effectiveness compared with the single treatments. Results further suggested that antifibrotic mechanisms were involved in inhibiting CXCL14 and MMP2/MMP9 expression, and preventing the activation of Smad2/3 and hedgehog signaling pathways. The combined use of Dxs and BBR may represent a potential therapeutic approach for PF.
引用
收藏
页码：2385 / 2392
页数：8
相关论文
共 26 条
  • [1] Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology
    Chakrabarti, S
    Patel, KD
    [J]. EXPERIMENTAL LUNG RESEARCH, 2005, 31 (06) : 599 - 621
  • [2] Chen MM, 2013, ZHONG FENG YU SHEN J, V32, P577
  • [3] Chen X L, 2011, PROG MOD BIOMED, V23, P4609
  • [4] Berberine inhibits Smad and non-Smad signaling cascades and enhances autophagy against pulmonary fibrosis
    Chitra, Palanivel
    Saiprasad, Gowrikumar
    Manikandan, Ramar
    Sudhandiran, Ganapasam
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2015, 93 (09): : 1015 - 1031
  • [5] Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: A biphasic experimental study
    Chitra, Palanivel
    Saiprasad, Gowrikumar
    Manikandan, Ramar
    Sudhandiran, Ganapasam
    [J]. TOXICOLOGY LETTERS, 2013, 219 (02) : 178 - 193
  • [6] Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis
    Corbel, M
    Belleguic, C
    Boichot, E
    Lagente, V
    [J]. CELL BIOLOGY AND TOXICOLOGY, 2002, 18 (01) : 51 - 61
  • [7] Novel therapeutic approaches for pulmonary fibrosis
    Datta, Arnab
    Scotton, Chris J.
    Chambers, Rachel C.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (01) : 141 - 172
  • [8] Nicorandil ameliorates pulmonary inflammation and fibrosis in a rat model of silicosis
    El-Kashef, Dalia H.
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 64 : 289 - 297
  • [9] Ishii T., 2012, PATHOGENESIS BIOMARK, pA5178
  • [10] CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis
    Jia, Guiquan
    Chandriani, Sanjay
    Abbas, Alexander R.
    DePianto, Daryle J.
    N'Diaye, Elsa N.
    Yaylaoglu, Murat B.
    Moore, Heather M.
    Peng, Ivan
    DeVoss, Jason
    Collard, Harold R.
    Wolters, Paul J.
    Egen, Jackson G.
    Arron, Joseph R.
    [J]. THORAX, 2017, 72 (09) : 780 - 787
123